ARMP
Armata Pharmaceuticals, Inc. (AMEX)
Healthcare — Biotechnology
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
None
2 analysts
$5.24
+$0.08 (+1.55%)
Target:
$17.50
(234.0%)
Sign in to add ARMP to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $237.89M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.13 |
| EPS (TTM) | $-7.78 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 60.70% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $17.50 |
| Analysts | 2 |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 36.7 |
| Beta | 1.23 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.34 |
| 52-Week Low | $1.85 |
| 50-Day Avg | $8.72 |
| 200-Day Avg | $7.34 |
| Avg Volume | 142.8K |
| Volume | 110.7K |
Performance Analysis
NEUTRALARMP presents a mixed picture with both positive and negative indicators.
~
Trading at 23% of its 52-week range.
~
RSI at 36.7 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 60.7% year-over-year.
~
Wall Street consensus is "none" from 2 analysts.
+
Average analyst target of $17.50 implies 234.0% upside.
Recent News
Loading news...
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report